期刊
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
卷 14, 期 3, 页码 154-219出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/15622975.2013.770551
关键词
Bipolar disorder; Maintenance; Prophylaxis; Pharmacotherapy; Antipsychotics
类别
资金
- Astra Zeneca
- BMS
- Desitin
- Eli Lilly
- Gedeon-Richter
- Hoffmann-LaRoche
- Janssen-Cilag
- Lundbeck
- Merck
- Otsuka
- Sanofi-Aventis
- Servier
- Sepracor
- UBC
- Bristol-Myers Squibb
- Forest Research Institute
- Gedeon Richter
- Glaxo-Smith-Kline
- Janssen
- Jazz
- Johnson Johnson
- Merck-Sharp and Dohme
- Novartis
- Pfizer Inc
- Roche
- Shering-Plough
- Solvay
- Takeda
- Teva
- Bristol Myers-Squibb
- Organon
- Boehringer-Ingelheim
- Cephalon/Teva
- Eisai
- P1Vital
- GSK
- Sunovion
- National Institute of Mental Health
- Janssen Cilag
- Pfizer
- Sanofi
- Schering-Plough
- Schwabe
- Wyeth
- German Science Foundation
- German Ministry of Science
- German Ministry of Health
Objectives. These guidelines are based on a first edition that was published in 2004, and have been edited and updated with the available scientific evidence up to October 2012. Their purpose is to supply a systematic overview of all scientific evidence pertaining to the long-term treatment of bipolar disorder in adults. Methods. Material used for these guidelines are based on a systematic literature search using various data bases. Their scientific rigor was categorised into six levels of evidence (A-F) and different grades of recommendation to ensure practicability were assigned. Results. Maintenance trial designs are complex and changed fundamentally over time; thus, it is not possible to give an overall recommendation for long-term treatment. Different scenarios have to be examined separately: Prevention of mania, depression, or an episode of any polarity, both in acute responders and in patients treated de novo. Treatment might differ in Bipolar II patients or Rapid cyclers, as well as in special subpopulations. We identified several medications preventive against new manic episodes, whereas the current state of research into the prevention of new depressive episodes is less satisfactory. Lithium continues to be the substance with the broadest base of evidence across treatment scenarios. Conclusions. Although major advances have been made since the first edition of this guideline in 2004, there are still areas of uncertainty, especially the prevention of depressive episodes and optimal long-term treatment of Bipolar II patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据